We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock

Delisted

GTHX was delisted on the 17th of September, 2024.

98 hedge funds and large institutions have $98.2M invested in G1 Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 21 increasing their positions, 33 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

188% more call options, than puts

Call options by funds: $463K | Put options by funds: $161K

15% less funds holding

Funds holding: 11598 (-17)

36% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 39

36% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 33

47% less capital invested

Capital invested by funds: $184M → $98.2M (-$86M)

Holders
98
Holders Change
-17
Holders Change %
-14.78%
% of All Funds
1.65%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
25
Increased
21
Reduced
33
Closed
39
Calls
$463K
Puts
$161K
Net Calls
+$302K
Net Calls Change
-$301K

GTHX Hedge Fund Activity: Q2 2022 in Review

98 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q2 2022, worth a combined $98.2M — down 47% from $184M a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of GTHX and 25 opened new positions — a net loss of 14 holders — while 33 trimmed existing stakes and 21 added.

The largest buyer was Woodline Partners, opening a new position worth an estimated $9.95M. The largest seller was State Street, cutting an estimated $19.6M.

  • 98 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q2 2022, down from 115 in Q1 2022.
  • Funds reported $98.2M of G1 Therapeutics, Inc. Common Stock stock for Q2 2022, down 47% quarter-over-quarter.
  • 25 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q2 2022 and 39 closed out, a net change of -14 holders.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q2 2022 was Woodline Partners, an estimated $9.95M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q2 2022 was State Street, an estimated $19.6M sold.

Based on aggregated 13F filings for Q2 2022.